Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.
| Published in | American Journal of Psychiatry and Neuroscience (Volume 3, Issue 5) |
| DOI | 10.11648/j.ajpn.20150305.12 |
| Page(s) | 90-93 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Atomoxetine-Pharmacology-Clinical Uses-Off Label Uses
| [1] | Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26 |
| [2] | Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711 |
| [3] | Ding YS, Naganawa M, Gallezot JD et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage. 2014;86:164-71 |
| [4] | Ludolph AG, Udvardi PT, Schaz U, et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010;160(2):283-91 |
| [5] | Kobayashi T, Washiyama K, Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxitine. Neuropsychopharmacology. 2010;35(7):1560-9 |
| [6] | Creighton CJ, Ramabadran K, Ciccone PE, et al. Synthesis and biological evaluation of the major metabolite of atomoxetine : elucidation of a partial kappa-opioid agonist effect. Bioorg Med Chem Lett. 2004;14(15):4083-5 |
| [7] | Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-24 |
| [8] | Berigan TR. Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim Care Companion J Clin Psychiatry. 2004;6(2):93-94 |
| [9] | Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline : a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-7 |
| [10] | Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448-55 |
| [11] | Ravindran LN, Kim DS, Letamendi AM, et al. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009;29(6):561-4 |
| [12] | McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder : a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390-8 |
| [13] | Ball MP, Warren KR, Feldman S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizphr Relat Psychoses. 2011;5(1):17-25 |
| [14] | Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008;28(1):59-63 |
| [15] | Kelly DL, Buchanan RW, Boggs DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009;70(4):518-25 |
| [16] | Naguy A, Al-Mutairi H. Add-on atomoxetine mitigated different symptom domains in a case of Early-onset schizophrenia. J Psychiatry. 2015;18:279 |
| [17] | Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-8 |
| [18] | Jancovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8 |
| [19] | Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson’s Disease : a pilot open-label study. Mov Disord. 2009;24(2):277-82 |
| [20] | Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484-7 |
| [21] | Mohs RC, Shiovitz TM, Tariot PN, et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease : 6-month, randomized, double-blind, placebo-controlled, parallel trial study. Am J Geriatr Psychiatry. 2009;17(9):752-9 |
| [22] | Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders : placebo-controlled cross-over pilot study. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-205 |
| [23] | Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711 |
| [24] | Shatkin JP. Atomoxetine for the treatment of pediatric nocturnal enuresis. J Child Adolesc Psychopharmacol. 2004;14(3):443-7 |
| [25] | Clark N. Conventional Antipsychotic and clozapine-induced urinary incontinence. JCPNP. 2003;2(2). |
APA Style
Ahmed Naguy, Ali Al-Tajali. (2015). Atomoxetine Beyond ADHD: A Fact or Aritfact. American Journal of Psychiatry and Neuroscience, 3(5), 90-93. https://doi.org/10.11648/j.ajpn.20150305.12
ACS Style
Ahmed Naguy; Ali Al-Tajali. Atomoxetine Beyond ADHD: A Fact or Aritfact. Am. J. Psychiatry Neurosci. 2015, 3(5), 90-93. doi: 10.11648/j.ajpn.20150305.12
AMA Style
Ahmed Naguy, Ali Al-Tajali. Atomoxetine Beyond ADHD: A Fact or Aritfact. Am J Psychiatry Neurosci. 2015;3(5):90-93. doi: 10.11648/j.ajpn.20150305.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajpn.20150305.12,
author = {Ahmed Naguy and Ali Al-Tajali},
title = {Atomoxetine Beyond ADHD: A Fact or Aritfact},
journal = {American Journal of Psychiatry and Neuroscience},
volume = {3},
number = {5},
pages = {90-93},
doi = {10.11648/j.ajpn.20150305.12},
url = {https://doi.org/10.11648/j.ajpn.20150305.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20150305.12},
abstract = {Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.},
year = {2015}
}
TY - JOUR T1 - Atomoxetine Beyond ADHD: A Fact or Aritfact AU - Ahmed Naguy AU - Ali Al-Tajali Y1 - 2015/08/06 PY - 2015 N1 - https://doi.org/10.11648/j.ajpn.20150305.12 DO - 10.11648/j.ajpn.20150305.12 T2 - American Journal of Psychiatry and Neuroscience JF - American Journal of Psychiatry and Neuroscience JO - American Journal of Psychiatry and Neuroscience SP - 90 EP - 93 PB - Science Publishing Group SN - 2330-426X UR - https://doi.org/10.11648/j.ajpn.20150305.12 AB - Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence. VL - 3 IS - 5 ER -
Email: